威望生物制药公司专利了新的皮下抗体输送平台, Prestige Biopharma patents new subcutaneous antibody delivery platform for sustained release.

威望生物制药公司已申请了一种新的皮下抗体输送平台, 名为IDC224. Prestige Biopharma IDC has filed a patent for a new subcutaneous antibody delivery platform called IDC224. 这种技术使用由体温触发的液态凝转换,使药物持续释放并减少剂量频率. This technology uses a liquid-to-gel transition triggered by body temperature to enable sustained drug release and reduce dosing frequency. 它的设计使抗体治疗比传统输液更方便,并正在与Prestige的trastuzumab生物类似剂一起使用. It is designed to make antibody treatments more convenient than traditional IV infusions and is being explored for use with Prestige's trastuzumab biosimilar.